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ARTICLE INFO    ABSTRACT 
Article type: 
Original Article 
  Introduction:  Increased  bleeding  is  the  most  common  cause  of  intrauterine  device 
(IUD) removal. The use of alternative therapies to treat bleeding has increased due to 
the complications of medications. But most alternative therapies are not accepted by 
women.  Therefore,  conducting  studies  to  find  the  right  treatment  with  fewer 
complications  and  being  acceptable  is  necessary.  This  study  aimed  to  compare  the 
effect of mefenamic acid and vitex agnus castus on IUD induced bleeding. 
 Methods:  This  was  a  double  blinded  randomized  controlled  clinical  trial.  It  was 
conducted on 84 women with random allocation in to two groups of 42 treated with 
mefenamic acid and vitex agnus capsules taking three times a day during menstruation 
for four  months. Data  were  collected by demographic questionnaire and Higham 5 
stage chart (1 month before the treatment and 4 months during the treatment)., Paired t-
test, independent t-test, chi-square test, analysis of variance (ANOVA) with repeated 
measurements, and SPSS software were used to determine the results. 
 Results:  Mefenamic  acid  and  vitex  agnus  significantly  decreased  bleeding.  This 
decrease in month 4 was 52% in the mefenamic acid group and 47.6% in the vitex 
agnus group. The mean bleeding score changes was statistically significant between the 
two groups in the first three months and before the intervention. In the mefenamic acid 
group,  the  decreased  bleeding  was  significantly  more  than  the  vitex  agnus  group. 
However,  during  the  4
th  month,  the  mean  change  was  not  statistically  significant. 
Conclusion: Mefenamic acid and vitex agnus  were both  effective on IUD induced 
bleeding; however, mefenamic acid was more effective. 
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Introduction  
Intrauterine  device  (IUD)  is  a  key  part  of 
modern contraception. More than 130 million 
women worldwide use it due to its length of 
effect, high impact in contraception, and its 
low cost compared to other methods.1,2 IUD 
effectiveness during 10 years of use is about 
99.2-99.4%  which  is  comparable  to  tubal 
ligation (TL).3-5 
With  the  exception  of  progesterone  IUD, 
50-100%  of  all  types  of  IUDs  increase 
menstruation  blood  compared  to  its  pre-
placement.6,7 Among 160 million women who 
use  IUD  worldwide8  about  48%  suffering 
from  excessive  bleeding,  which  is  often 
associated  with  discomfort  or  pain  in  the 
lower  abdomen.9  IUD  induced  bleeding 
appears  in  various  ways  such  as  increased 
bleeding in menstrual cycles of more than 80 
ml,  and  increased  duration  of  bleeding 
during  menstrual  period.7  The  reason  of 
bleeding  in  women  using  IUD  is 
multifactorial.  Increased  local  fibrinolytic 
activity  is  the  main  cause  of  menstruation 
blood.  Another  reason  for  the  increased 
bleeding  is  increased  prostaglandin  which 
IUD may cause.10 IUD induced bleeding may Yavarikia et al. 
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be annoying and makes women reluctant to 
use this method.11 Therefore, instead of using 
IUD, they ask for early sterilization, or choose 
less effective and inappropriate methods that 
puts  them  in  the  risk  of  unwanted 
pregnancy.7,12,13  For  the  treatment  of 
functional  uterine  bleeding,  if  IUD  is  used, 
several  medical  procedures  exist  including 
anti-fibrinolytic therapies such as tranexamic 
acid,  nonsteroidal  anti-inflammatory  drugs, 
combined  contraceptive  pills,  progesterone, 
and danazol.14-17 Since the majority of medical 
treatments  used  to  control  bleeding  are 
associated  with  several  complications,  many 
non-pharmaceutical procedures that are used 
in most countries have grown recently among 
which herbal therapy is another one.16-18 
Herbal  therapies  and  homeopathic 
treatments are natural alternatives and can be 
used  to  regulate  the  menstrual  cycle. 
Compared  to  other  medications,  herbal 
remedies  have  fewer  complications  for  the 
immune  system.  Many  plants  through 
balancing  the  body's  hormone  levels  can 
reduce  uterine  severe  bleeding.  In addition, 
herbal medicines can reduce menstrual pain 
and  cramping  caused  by  severe  bleeding. 
Some  of  the  plants  functions  are  anti-
inflammatory  which  acts  to  remove  water 
and help in relaxation.18 
One  of  the  plants  to  reduce  bleeding  is 
vitex agnus castus. This plant grows in warm 
regions of the world. This is a local plant of 
the  Mediterranean,  Central  Asia,  Italy,  and 
Germany,19,20 and is also local in Iran and has 
a  long  history  of  herbal  therapy  and 
traditional  medicine  in  many  parts  of  the 
world.19  Vitex  agnus  castus  has  long  been 
used in traditional medicine; it belongs to the 
mint  family  and  is  a  shrub  with  purple 
needle leaves.21 It is used for the treatment of 
infertility,  menstrual  disorders  including 
premenstrual  syndrome,  dysmenorrhea, 
menorrhagia, secondary amenorrhea, uterine 
inflammation,  pre-menopausal  disorders, 
acne,  fibrocystic  breast  disease  and 
hyperprolactinemia.22,23 Vitex angus increases 
the production of luteinizing hormone (LH) 
and  mildly  inhibits  the  release  of  follicle 
stimulating  hormone  (FSH)  resulting  in  a 
diversion  of  the  amount  of  estrogen  to 
progesterone.24  In  Iran,  in  1991  research  on 
botany, agriculture, and pharmacognosy and 
its production began, and from 1996 a drug 
called  ”vitex  agnus”  was  produced  and 
supplied  to  the  pharmaceutical  market  in 
Iran.25 
Mercorio et al.26 conducted a study on 24 
women with  IUD  who were  suffering from 
severe menstrual bleeding. The subjects were 
separated  into  two  groups  of  receiving  500 
mg mefenamic acid 3 times a day for 5 to 8 
days and recipients of desmopressin 500 mcg 
for  5  days.  The  subjects  were  asked  to 
continue  their  treatment  for  3  menstrual 
periods.  After  the  treatment,  menstrual 
bleeding significantly reduced in both groups 
and  there  was  no  statistically  significant 
difference between the two groups. Bleeding 
was  reduced  to  75%  in  the  mefenamic  acid 
recipients  and  80%  in  the  group  receiving 
desmopressin. The women in this study were 
divided into two groups of receiving 500 mg 
mefenamic acid 3 times a day for 5 days and 
the  placebo  group.  In  this  study,  menstrual 
irregularities  included  severe  bleeding, 
bleeding  between  menstruations  and 
spotting.  Statistical  significant  differences 
between  groups  were  observed  in  reducing 
bleeding after 1 month of treatment.27  
In  a  study  on  51  women  who  had 
excessive  bleeding,  25  women  used 
levonorgestrel  IUD  and  26  women  received 
oral mefenamic acid. The mean reduction in 
menstrual  blood  after  6  menstrual cycles  in 
the group with levonorgestrel IUD was 5 ml 
and  in  the  group  receiving  mefenamic  acid 
was  100  ml.25  Another  study  on  48  women 
using  depot  medroxy  progesterone  acetate 
(DMPA)  who  were  suffering  from 
menstruation severe bleeding. In this study, 
23 women received mefenamic acid capsule 
and 25 received placebo as the treatment. In a 
short  period  of  treatment,  statistically 
significant difference was observed between 
the two groups in the amount of menstrual Anti-bleeding effects of vitex agnus castus and mefenamic acid 
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bleeding.28 A study in the Aromatic Medical 
Center  showed  that  vitex  agnus  reduced 
bleeding.29  A  research  on  57  women  with 
severe  menstrual  bleeding  (menorrhagia) 
who  were  treated  with  vitex  agnus  drops 
showed  that  40  patients  after  the  period  of 
treatment had significantly been improved.30 
Considering the increased bleeding in half 
of  women  using  IUD,  some  clients  do  not 
choose this safe and effective method or even 
if they select it, they would be anxious while 
using IUD and feel uncomfortable due to its 
bleeding. The increasing numbers of women 
using the IUD is an important public health 
aim  and  the  role  of  midwives  in  family 
planning  and  population  control  are 
important,  and  consequently  improving  the 
quality  of  family  planning  and  care  is  the 
primary  principles  of  midwifery.  Studies 
refer  to  the  vitex  agnus  treatment  effect  on 
the reduction of abnormal uterine bleeding, 
and they show that vitex agnus has less side 
effects  compared  to  the  mefenamic  acid.24 
IUD induced bleeding is one of the common 
and  uncomfortable  complications  among 
women  using  this  method.  Among  the 
recommended  herbal  therapies,  vitex  agnus 
with  similar  treatment  mechanism  has 
minimal side effects and it is convenient to be 
used  due  to  its  positive  affects.24  Therefore, 
this  study  was  conducted  to  evaluate  the 
effectiveness of vitex agnus on IUD induced 
bleeding, and it is hoped to use the results in 
improving  the  quality  of  family  planning 
services, increase the use of this method and 
finally improve the maternal health. 
Materials and methods 
This was a double blinded clinical trial study. 
The target population were married women 
in  reproductive  age  (15-40  years  old)  who 
referred to Shohadaye Fardis Health Medical 
Center in 2012 (the reason for choosing this 
center was because of the high rate of IUD 
placement which was an average of 30 cases 
per  month).  Besides,  this  study  aimed  to 
determine  the  effectiveness  of  mefenamic 
acid  and  vitex  agnus  on  IUD  induced 
bleeding. 
Stata Statistical Software, Release 9.2 (Stata 
Corporation, College Station, TX, USA) was 
used  to  determine  the  sample  size.  The 
number of subjects according to the available 
data from a study was estimated 42 subjects 
for each group (Mean1 = 100, Mean2 = 134; 
SD1 = SD2 = 15; Power = 0.80, α = 0.05, n = 
38).24  Inclusive  criteria  included  lack  of 
medicine sensitivity or allergy, within three 
months  of  placing  the  IUD,  IUD  induced 
bleeding,  not  having  constraints  for  using 
mefenamic acid (peptic ulcer and allergy to 
this  medicine),  willingness  to  participate  in 
the  study,  having  minimal  literacy,  being 
younger than 40, no genital tract infections, 
and  gaining  a  minimum  score  of  100  in 
Higham chart. 
Data collection tool consisted of two parts. 
First part included the individual information 
(age,  education,  and  occupation)  and 
obstetric  history  (number  of  pregnancy, 
number of abortions, the time of the current 
IUD  insertion, history  of  breastfeeding,  and 
history  of  IUD  insertion).  And  the  second 
part  included  Higham  chart  which  was 
pictorial blood assessment chart (PBAC). This 
chart is a non-laboratory simple method for 
diagnosis  of  menorrhagia.  It  is  a  general 
scoring system which takes observing pads, 
tampons,  and  clot  appearing  as  the  basis. 
This method allows the comparison between 
the perceived bleeding and real blood loss. It 
is the best tool available for the assessment of 
menstrual blood loss with 86% sensitivity and 
89% accuracy.31 Since Higham chart is valid, 
there  was  no  need  for  its  retest  validity.  To 
determine the reliability, test-retest was used 
with 10 days intervals on 84 subjects (r = 0.91).  
After obtaining permission from the Ethics 
and Research Committee of Tabriz University 
of Medical Sciences, the researcher referred to 
the Shohadaye Fardis Health Medical Center 
and invited women with IUD to participate 
in the study by telephone calls. People who 
came  to  the  center  were  examined  by  a 
midwife and if they had the inclusive criteria, Yavarikia et al. 
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the aim of the study was explained to them 
and written consent was obtained from them 
(Chart  1).  Then  information  about  Higham 
chart and the method it works was given to 
them. And they were asked to complete the 
chart  during  their  bleeding  so  that  during 
menstrual  period,  they  should  mark  the 
number of pads in the boxes that show the 
intensity of bleeding. If the blood spots on the 
pad were light or less than 50%, score 1 could 
be given, if the blood spots were medium and 
50% of a pad was contaminated, score 5 could 
be  given,  and  if  it  was  completely  stained 
with blood or more than 50% of the pad was 
contaminated,  score  20  could  be  given.  If 
there was also a small clot score 1 and if there 
was  a  large,  score  5  could  be  given,31,32  and 
then  they  would  give  the  form  to  the 
researcher.  Participants  bleeding  were 
assessed  by  the  researcher.  Women  whose 
their  bleeding  scored  at  100  and  over,  were 
chosen  for  the  study  subjects.  Score  100  or 
over indicated abnormal bleeding and should 
be  treated.  Score  less  than  100  indicated 
normal  bleeding  for  women.  In  case  of  any 
possible  complications,  the  women  were 
asked  to  write  down  their  problems  in  the 
complication form so that the researcher was 
aware and could make a decision, if necessary. 
 
 
 
Chart 1. Flowchart of the study subjects 
 
Competency assessment (n = 122)  
Assigned to vitex agnus group (n = 42)   Assigned to mefenamic acid group (n = 42)  
 
Individuals who removed IUD due to severe 
bleeding (n = 1) 
IUD removal due to pregnancy (n = 1) 
Mefenamic acid-related complications 
including:  
Nausea (n = 1)  
Abdominal pain (n = 0)  
Received the allocated intervention (n = 42) 
 
Were analyzed in the first month (n = 42)  
Were excluded from the analysis (n = 0)  
Were analyzed in the second month (n = 41)  
Were excluded from the analysis due to 
severe bleeding (n = 1)  
Were analyzed in the third month (n = 39)  
Were excluded from analysis due to nausea 
and IUD removal due to pregnancy (n = 2) 
Were analyzed in the fourth month (n = 39) 
Were excluded from the analysis (n = 0) 
Individuals who removed IUD due to 
severe bleeding (n = 1) 
IUD removal due to pregnancy (n = 1) 
Vitex agnus-related complications 
including:  
Nausea (n = 1)  
Abdominal pain (n = 1)  
Received the allocated intervention 
(n = 42) 
 
Were analyzed in the first month (n = 42)  
Were excluded from the analysis (n = 0)  
Were analyzed in the second month (n = 41)  
Were excluded from the analysis due to 
severe bleeding (n = 1)  
Were analyzed in the third month (n = 39)  
Were excluded from analysis due to 
abdominal pain and IUD removal due to 
pregnancy (n = 2)  
Were analyzed in the fourth month (n = 38)  
Were excluded from the analysis due to 
abdominal pain (n = 1) Anti-bleeding effects of vitex agnus castus and mefenamic acid 
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The  random  allocation  of  individuals  in 
groups  was  done  by  computer  random 
number table with random blocks of 4 and 6. 
Participants  were  randomly  assigned  into 
two  groups,  i.e.  mefenamic  acid  and  vitex 
agnus. The researcher and the patients were 
not aware of the medication allocation in any 
groups. It was explained to the participants 
that in order to keep the random assigning of 
the subjects, the possibility of being assigned 
to  the  groups  was  the  same,  and  even  the 
researcher  did  not  know  who  would  be 
placed in which group. Each participant was 
given  a  sealed  envelope  (all  the  envelopes 
had  similar  appearance)  by  the  researcher 
and they were numbered from 1 to 84. The 
envelopes  contained  4  packs  of  mefenamic 
acid of 4 packs of vitex agnus. The subjects 
were  asked  to  take  one  pack  from  the 
envelope and use it 3 times a day from the 
first day of menstruation until the day 8, and 
complete  the  treatment  for  4  months. 
Mefenamic acid capsule was 250 mg product 
of  Poursina  Company,  and  the  vitex  agnus 
capsule was similar to the mefenamic acid in 
color and size which was made in School of 
Pharmacy  of  the  University  of  Tabriz.  The 
individuals  were  also  given  a  package  of 
sanitary pads with the same brand, size, and 
absorbency. The reason for giving them the 
same  pads  was  for  having  the  same 
assessment  of  the  bleeding  amount.  Then 
each  subject  in  each  month  during  the 
menstruation  and  simultaneous  with  taking 
medication completed the Higham chart. All 
statistical analyses were performed with SPSS 
for  Windows  13.0  (SPSS  Inc.,  Chicago,  IL, 
USA).  Data  normality  was  confirmed  by 
Kolmogorov-Smirnov  test.  According  to  the 
normal  distribution  of  the  data  in  order  to 
compare  the  means,  independent  t-test, 
paired t-test, analysis of variance (ANOVA) 
with  repeated  measures  were  done  and  for 
the  demographic  characteristics,  obstetric 
information, and chi-square test was used for 
the  amount  of  medication  complications. 
P-value < 0.05 was set as a significant level. 
Results 
In  this  study,  there  was  no  statistically 
significant difference between the two groups 
regarding  subject  distribution  in  age  groups, 
education, and occupation (p > 0.050) (Table 1). 
There  was  also  no  statistically  significant 
difference between the mefenamic acid group 
and  vitex  agnus  regarding  obstetric 
information according to the t-test (Table 2). 
Comparing  the  mean  score  of  bleeding 
before  and  1,  2,  3,  and  4  months  after  the 
intervention,  there  was  a  statistically 
significant  in  mefenamic  acid  group 
according  to  paired  t-test.  Furthermore,  
 
Table 1. Demographical characteristic of the study subjects in the two groups 
 
Demographical information  Mefenamic acid group 
(n = 42) 
Vitex agnus group 
(n = 42)  Statistical indicators 
Age (years)     
t = 1.95 
df = 81.75 
p = 0.054 
< 20  1 (2.4)  0 (0.0) 
21-25  11 (26.2)  3 (7.1) 
26-30  9 (21.4)  15 (35.7) 
31-35  16 (38.1)  16 (38.1) 
36-40  5 (11.9)  8 (19.0) 
Mean (SD)  29.74 (4.99)  31.81 (4.72) 
Education     
χ
2 = 0.48 
df = 3 
p = 0.920 
Primary  1 (2.4)  2 (4.8) 
Secondary  6 (14.3)  7 (16.7) 
High school  8 (19.0)  8 (19.0) 
Diploma and higher  27 (64.3)  25 (59.5) 
Occupation      χ
2 = 0.00 
df = 1 
p = 1.000 
Housewife  36 (85.7)  36 (85.7) 
Employee  6 (14.3)  6 (14.3) Yavarikia et al. 
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Table 2. Obstetric profile of the participants in the two groups 
 
Obstetric profile  Mefenamic acid group 
(n = 42) 
Vitex agnus group 
(n = 42)  Statistical indicators 
Number of pregnancies      χ
2 = 0.20 
df = 2 
p = 0.900 
1  19 (45.2)  21 (50.0) 
2  15 (35.7)  14 (33.3) 
3  8 (19.0)  7 (16.7) 
History of abortion      χ
2 = 0.10 
df = 1 
p = 0.740 
Yes  5 (11.9)  6 (14.3) 
No  37 (87.1)  36 (85.7) 
Current IUD
* placement (month)     
t = 1.40 
df = 77.02 
p = 0.160 
Less than 6 months  6 (14.3)  7 (16.7) 
6-12 months  14 (33.3)  18 (42.19) 
Over 12 months  22 (52.4)  17 (40.5) 
Mean (SD)  25.81 (23.11)  19.50 (17.82) 
Breast-feeding      χ
2 = 2.02 
df = 1 
p = 0.150 
Yes  5 (11.9)  10 (23.8) 
No  37 (88.1)  32 (76.2) 
History of using IUD      χ
2 = 0.06 
df = 1 
p = 0.790 
Yes  9 (21.4)  10 (23.8) 
No  33 (78.6)  32 (76.2) 
* Intrauterine device 
 
according to table 3, there was a statistically 
significant in vitex agnus group before and 1, 
2,  3,  and  4  months  after  the  intervention 
based on paired t-test. During the 4 months 
of intervention in the mefenamic acid group, 
3 subjects were excluded from the study due 
to  drug  complication  (nausea),  heavy 
bleeding  and  IUD  removal  due  to  fertility. 
And in the vitex agnus group, 4 subjects were 
excluded  because  of  the  same  reasons  i.e. 
drug  complication  (nausea  and  abdominal 
pain), and the other two reasons. According 
to  the  chi-square  test,  there  was  no 
statistically significant difference between the 
two groups (p = 0.500). 
The results also showed that changes in 
the  mean  scores  of  bleeding  between  the 
two  groups  during  the  first,  second,  and 
third  months  were  statistically  significant 
with  statistical  t-test.  Decrease  in  the 
mefenamic  acid  group  was  significantly 
greater than the vitex agnus group. While 
in  the fourth month,  changes  in the mean 
scores of bleeding between the two groups 
were not statistically significant (p = 0.110) 
(Table 4). Results of ANOVA with repeated 
measures  in  the  5  cycles  between  the  two 
groups  were  statistically  significant  
(p < 0.001) (Table 4). 
 
Discussion 
The  results  indicated  that  both  mefenamic 
acid  and  vitex  agnus  significantly  reduced 
the menstrual bleeding in patients suffering 
from severe IUD induced bleeding. In month 
4 compared to the pre-intervention phase in 
the group receiving mefenamic acid capsule, 
bleeding  was  reduced  to  52%  and  in  the 
group  treated  with  vitex  agnus  reduced  to 
47.61%.  Zamani  quoted  from  Hayner  et  al. 
showed that treatment with mefenamic acid 
significantly  reduced  menstrual  bleeding 
(2-78%).24  In  Irvine  study,  two  hormonal 
combined oral contraceptive pill (OCP) and 
danazol,  and  two  non-steroidal  analgesic 
compounds (mefenamic acid and naproxen) 
were  compared  in  the  treatment  of 
menorrhagia.  Menstrual  bleeding  reduction 
of  20-32%  with  mefenamic  acid,  12%  with 
naproxen,  43%  with  OCP,  and  49%  with 
danazol  were  observed.33  In  a  study  by 
Kouides,  a  comparison  of  mefenamic  acid 
and  tranexamic  acid  in  the  treatment  of 
menorrhagia  showed  that  they  reduced  the 
   Anti-bleeding effects of vitex agnus castus and mefenamic acid 
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Table 3. Mean bleeding scores before and after the intervention during 4 months in the two groups 
 
  Mefenamic acid group  Vitex agnus group  Statistical 
indicators  n  Mean (SD)  n  Mean (SD) 
Mean bleeding score before the 
intervention 
42  181.50 (55.38)  42  171.14 
(54.01) 
t
* = -0.86 
df = 81.94 
p = 0.380 
Mean bleeding score 1 month after 
the intervention 
42  158.76 (43.74)  42  165.71 
(53.24) 
t
* = 3.16 
df = 82 
p = 0.002 
Mean bleeding score 2 months 
after the intervention 
41  121.61 (40.32)  41  144.76 
(37.96) 
t
* = 4.08 
df = 80 
p < 0.001 
Mean bleeding score 3 months 
after the intervention 
39  100.28 (37.13)  39  106.59 
(29.85) 
t
* = 2.02 
df = 76 
p = 0.040 
Mean bleeding score 4 months 
after the intervention  39  87.26 (30.47)  38  89.66 
(22.00) 
t
* = 1.57 
df = 72.46 
p = 0.110 
Statistical indicators before and 1 
month after the intervention 
p < 0.001; df = 41; 
†t = 4.43  p = 0.006; df = 41; t
† = 2.80 
Statistical indicators before and 2 
months after the intervention 
p < 0.001; df = 40; 
†t = 7.05  p < 0.001; df = 40; t 
†= 5.46 
Statistical indicators before and 3 
months after the intervention 
p < 0.001; df = 38; 
†t = 9.76  p < 0.001; df = 38t; 
† = 9.79 
Statistical indicators before and 4 
months after the intervention 
p < 0.001; df = 38; 
†t = 11.23  p < 0.001; df = 37; t
† = 11.26 
* t-test, 
† Paired t-test 
 
Table 4. Mean changes of bleeding scores based on follow-up in the two groups of mefenamic acid 
and vitex agnus group 
 
  Mefenamic acid group  Vitex agnus group  MD
† (95%CI)  Statistical 
indicators  n  Mean (SD)  n  Mean (SD) 
Mean changes 1 month 
after and before the 
intervention 
42  -22.64 (33.10)  42  -5.42 (12.25)  17.21  
(6.28, 37.04) 
t
* = 3.16 
df = 82 
p = 0.002 
Mean changes 2 months 
after and before the 
intervention 
41  -58.97 (53.55)  41  -21.29 (24.94)  37.68  
(32.04, 19.56) 
t
* = 4.08 
df = 80 
p < 0.001 
Mean changes3 months 
after and before the 
intervention 
39  -79.41 (50.78)  39  -58.92 (37.58)  20.48  
(40.63, 0.33) 
t
* = 2.02 
df = 80 
p = 0.040 
Mean changes 4 months 
after and before the 
intervention 
39  -92.43 (51.40)  38  -75.65 (41.41)  16.77  
(-40.95, 4.37) 
t
* = 1.57 
df = 72.46 
p = 0.110 
ANOVA with repeated 
measures testing within 
subjects 
F = 78.30 
df = 1.88 
p < 0.001 
F = 90.15 
df = 1.95 
p < 0.001 
*t-test, †Mean difference (confidence Interval) 
 
bleeding  to  20%  with  mefenamic  acid  and 
54%  with  tranexamic  acid.34  Reid  and 
Virtanen-Kari reported a reduction of 100 ml 
in  menstrual  bleeding  of  women  suffering 
from  menorrhagia  by  mefenamic  acid. 
Furthermore,  the  complication  caused  by 
mefenamic  acid  was  5%  which  was  in 
accordance  with  the  present  study.35  In  a 
study  by  Najam  et  al.,  the  effects  of 
mefenamic  acid  and  tranexamic  acid  were Yavarikia et al. 
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compared and showed that mefenamic acid 
reduced  bleeding  to  59.3%.36  In  an 
observational study by Dogan et al., 15 drops 
of  vitex  agnus  were  used  in  126  women  3 
times a day for several cycles. 33 women with 
polymenorrhea  responded  to  the  treatment 
and  58  women  were  treated  with 
menorrhagia.37 In a clinical study, vitex agnus 
treatment  resulted  in  a  significant 
improvement of 40 patients from 57 patients 
suffering from menorrhagia.21 In the present 
study, mefenamic acid caused 2% and vitex 
agnus caused 5% complications in the study 
subjects.  The  results  from  Zamani  et  al. 
showed  that  using  vitex  agnus  and 
mefenamic acid in patients with menorrhagia 
for 4 months reduced menstrual bleeding to 
65% and 80%, respectively and also increased 
hemoglobin  level.24  Moreover,  mefenamic 
acid caused 73% and vitex agnus caused 5% 
complications  in  the  patients  (P  >  0.050). 
Regarding the complication caused by vitex 
agnus  (5%),  this  result  was  in  accordance 
with  the  present  study;  however,  it  was 
inconsistent  regarding  the  mefenamic  acid 
complication  which  was  2%  in  the  present 
study. This difference might be due to lack of 
proper training in using this medication. 
The  effectiveness  mechanism  of  vitex 
agnus is not fully understood.38 Vitex agnus 
increases  the  production  of  LH  and  mildly 
inhibits  the  release  of  FSH,  resulting  in  a 
diversion  of  the  estrogen  amount  to 
progesterone that in fact is the same as the 
effect  of  luteinizing.12,38,39  Progesterone 
prevents  the  formation  of  multinucleate 
leukocytes in the stroma, therefore it will not 
be  formed  in  case  of  progesterone 
inflammatory  reaction  in  the  stroma.12  In 
addition,  another  effect  was  the  direct 
connection to the estrogen receptor.23,40 
Conclusion 
Mefenamic  acid  and  vitex  agnus  are  both 
effective  on  IUD  induced  bleeding,  but 
mefenamic  acid  was  more  effective.  Since 
midwives  are  allowed  to  use  traditional 
medicine  and  complementary  medicine 
according to the latest approved regulations 
by  the  Iranian  Ministry  of  Health,  and  the 
results  of  the  present  study  indicated  the 
effectiveness of herbal treatment on reducing 
IUD induced bleeding, herbal treatment as a 
new and simple option for the midwives of 
our  country  is  recommended  to  reduce 
bleeding  in  eligible  patients  of  the  family 
planning program. However, further studies 
are  needed  on  the  safety  and  quality  of 
medicinal plants. Since there are few studies 
on the effectiveness of vitex agnus on severe 
menstrual  bleeding,  further  studies  are 
recommended accordingly. The limitations of 
the study included the time limitation which 
prolonged  monitoring,  and  this  limitation 
was  controlled  by  the  random  sample 
selection. 
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